Preview Newsletter
Morcellation Media Monitoring 09/8/2015
-
Government Watchdog to Investigate Hysterectomy Device Found to Spread Uterine Cancer
Sep 4, 2015 | Wall Street Journal
By Jon Kamp
The U.S. Government Accountability Office confirmed Friday that it plans to investigate a surgical device that was marketed for two decades before the Food and Drug Administration warned it can spread uterine cancer. Twelve lawmakers wrote the GAO a letter last month asking for a probe into laparoscopic power morcellators, which are bladed, drill-shaped tools gynecologists commonly used to cut up growths called fibroids in minimally invasive surgery, most often hysterectomies. The FDA last year estimated that women who undergo these procedures face 1-in-350 odds that they harbor an undetected cancer that a morcellator could spread and worsen. -
GAO to investigate medical device implicated in cancers
Sep 5, 2015 | The Philadelphia Inquirer
By Marie McCullough
The U.S. Government Accountability Office has agreed to investigate why an electric device used in gynecological surgery was marketed for two decades before safety warnings were issued by the Food and Drug Administration. The GAO, which investigates how the government spends tax dollars, sent a confirmatory letter to U.S. Rep Mike Fitzpatrick (R, Pa). He and 11 other members of Congress requested the probe last month. -
FDA and Lawyers Warn Cancer Patients of Morcellator Risks
Sep 7, 2015 | Newswire
By DE Brown
It’s been nearly a year since the U.S. Food and Drug Administration (FDA) issued a warning about the use of power morcellators and their relationship to uterine fibroids in surgical procedures. However, the debate and controversy surrounding these devices is still raging – both in courtrooms and hospitals. For doctors, patients, and their family members, it’s important that a definitive conclusion is reached. Either power morcellators need to be banned by the FDA, or they need to be deemed safe. -
Federal Watchdog Agency Will Probe Power Morcellators
Sep 8, 2015 | Medscape
By Robert Lowes
The US Government Accountability Office (GAO) is going to launch an investigation into controversial power morcellators. The devices shred uterine fibroids for easy removal through laparoscopic incisions. Critics say the devices accomplish that at the cost of endangering women's lives and therefore should be banned.In April 2014, the US Food and Drug Administration (FDA) warned against using power morcellators for hysterectomies or myomectomies in most women with uterine fibroids because of the risk of spreading occult uterine cancer, found in 1 in 350 women undergoing these procedures. Six months later the FDA added a boxed warning to product labels. -
GAO to Investigate Morcellator Device
Sep 8, 2015 | The Perimenopause Blog
Last month I wrote a post about a controversial procedure and device used to treat fibroid tumors in women. The procedure is called “morcellation” and the device used in the procedure is called a “power morcellator.” Approved by the FDA over two decades ago to be used in surgery to remove fibroid tumors, both the device and the procedure have been linked to the spread of uterine cancer in patients who underwent the procedure. -
Morcellator Cancer Lawsuit News: GAO To Investigate Power Morcellators In Response To Congress Members’ Request
Sep 5, 2015 | Southern Med Law
As morcellator cancer lawsuits continue to be filed around the country, The U.S. Government Accountability Office (GAO) has agreed to investigate claims that laparoscopic power morcellators spread cancer during gynecological surgeries. Southern Med Law filed the first power morcellator cancer lawsuit in a U.S. federal court. Katherine Siggerud, GAO’s managing director, sent a response on September 1 to U.S. Rep. Mike Fitzpatrick (R-Pa.), who led the 12-member bipartisan Congressional group in asking for the probe. The GAO conducts investigations for the U.S. Congress. -
California Couple Sue Gyrus ACMI Over Power Morcellator Cancer
Sep 8, 2015 | Top Class Actions
By Amanda Antell
A California couple has filed a power morcellator lawsuit against Gyrus ACMI, alleging that its product caused cancer to spread. Plaintiffs Kurt and Lisa N. claim in their power morcellator lawsuit that the device caused Lisa to develop uterine cancer after a physician used the device to perform a hysterectomy. -
Power Morcellator Poses Uterine Cancer Risks to Women
Sep 8, 2015 | Top Class Actions
By Karina Basso
Many women undergo gynecological surgeries for a variety of health reasons. Some common gynecological surgeries performed on women include: myomectomy (removal of fibroids), hysterectomy (removal of the uterus), oophorectomy (removal of the ovaries) ,salpingectomy (removal of fallopian tubes). However, according to recent research, women who undergo these surgeries have an increased risk of developing cancer in the two years after the procedure. This is especially true if the surgeries listed above were performed using a power morcellator device, a medical tool that has become quite controversial in the medical field because of their alleged tendency to spread cancer cells at the site of surgery.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Morcellation
Full Text of Stories Below
-
Government Watchdog to Investigate Hysterectomy Device Found to Spread Uterine Cancer
Sep 4, 2015 | Wall Street Journal
By Jon Kamp
The U.S. Government Accountability Office confirmed Friday that it plans to investigate a surgical device that was marketed for two decades before the Food and Drug Administration warned it can spread uterine cancer.
Twelve lawmakers wrote the GAO a letter last month asking for a probe into laparoscopic power morcellators, which are bladed, drill-shaped tools gynecologists commonly used to cut up growths called fibroids in minimally invasive surgery, most often hysterectomies. The FDA last year estimated that women who undergo these procedures face 1-in-350 odds that they harbor an undetected cancer that a morcellator could spread and worsen.
“We’ve agreed to do the work,” Katherine Siggerud, managing director for congressional relations at the GAO, confirmed Friday.
In a letter earlier this week to U.S. Rep. Mike Fitzpatrick (R., Pa.), a lawmaker at the forefront of pushing for a GAO review, Ms. Siggerud said the agency accepted his request “as work that is within the scope” of GAO authority. She said the GAO would likely have the staff available to begin its work in about five months.
She said in an interview it was too soon to tell how long a probe might take. An FDA spokesman said the agency will cooperate with any GAO review, and does not comment on pending or ongoing investigations.
The probe will likely add scrutiny to how the FDA handled issues with power morcellators going back to 1991—when the first one was cleared for sale in the U.S.—to last year, when the agency cited evidence that the risk of hidden uterine cancers called sarcomas was much higher than many gynecologists believed. Device applications and other records show the FDA knew early on that morcellators could spread dangerous cells, but the agency said the magnitude of that risk wasn’t recognized until the issue gained prominence starting in late 2013.
“I am glad the GAO has agreed to take up this investigation,” Mr. Fitzpatrick said in a statement. “What happened with the power morcellator should never happen again.”
Rep. Louise Slaughter (D., N.Y.) and 10 other members of Congress also signed the Aug. 7 letter to the GAO.
They asked for an investigation into issues such as the capabilities of a regulatory process the FDA used to clear all morcellators for sale in the U.S.; the process has drawn criticism for being too lenient. The lawmakers also asked to know whether groups like hospitals and device manufacturers complied with FDA rules to report problems with the devices, how doctors were trained to use them and what steps the FDA is taking to determine whether morcellators are safe to remain on the market.
The FDA has defended the regulatory process used to approve morcellators and most devices as a good way to balance innovation and safety, and said that the agency is strengthening its surveillance of devices on the market. Johnson and Johnson, formerly the largest morcellator maker before it voluntarily left the market last year, has said that it wasn’t aware of any reportable events regarding morcellators and the possibility of worsened cancer until late 2013.
The FDA in November followed up on its earlier morcellator advisory by calling for ablack-box warning, its strongest caution, regarding the cancer risks. The devices still remain on sale from other companies beyond J&J, although many hospitals and health insurers have curbed their use.
-
GAO to investigate medical device implicated in cancers
Sep 5, 2015 | The Philadelphia Inquirer
By Marie McCullough
The U.S. Government Accountability Office has agreed to investigate why an electric device used in gynecological surgery was marketed for two decades before safety warnings were issued by the Food and Drug Administration.
The GAO, which investigates how the government spends tax dollars, sent a confirmatory letter to U.S. Rep Mike Fitzpatrick (R, Pa). He and 11 other members of Congress requested the probe last month.
"GAO accepts your request as work that is within the scope of its authority," said the Sept. 1 letter, signed by GAO managing director Katherine Siggerud.
The tissue-slicing device, called a power morcellator, enables hysterectomies to be done through small rather than large abdominal incisions, but it can also spread and worsen an undetected uterine cancer.
Anesthesiologist Amy Reed suffered that horrible outcome following a hysterectomy at a Boston hospital in 2013. Since then, she and her husband, heart surgeon Hooman Noorchashm, have been campaigning for a ban on electric morcellators.
Noorchashm and Reed, who was recently treated for a second recurrence of her aggressive cancer, now live with their six children in the Philadelphia area.
"There's a lot of sugar-coating going on by industry and the FDA," Noorchashm said Friday. "I hope the GAO stands independent" as it investigates.
Fitzpatrick emailed: "I am glad the GAO has agreed to take up this investigation. What happened with the power morcellator should never happen again."
An FDA safety review of power morcellators, prompted by the push for a ban, concluded that up to one in 350 women undergoing hysterectomy with the device might have a hidden cancer - not the one in 10,000 risk that gynecologists cited after the device came on the market in 1993.
The FDA review led hospitals and insurers to sharply curtail use of the device.
-
FDA and Lawyers Warn Cancer Patients of Morcellator Risks
Sep 7, 2015 | Newswire
By DE Brown
It’s been nearly a year since the U.S. Food and Drug Administration (FDA) issued a warning about the use of power morcellators and their relationship to uterine fibroids in surgical procedures. However, the debate and controversy surrounding these devices is still raging – both in courtrooms and hospitals. For doctors, patients, and their family members, it’s important that a definitive conclusion is reached. Either power morcellators need to be banned by the FDA, or they need to be deemed safe.
The Problem with Morcellators
Technically speaking, there’s nothing wrong with power morcellators themselves. The devices work as advertised – cutting up large pieces of tissue into more manageable sections that can easily be removed from the body in a minimally invasive fashion. It’s what the device does when it comes into contact with undetected malignant cancer cells that’s troublesome and potentially deadly.
It’s been determined that when morcellators come into contact with cancer cells, they can actually spread those cells into other regions of the body that it previously had not reached. This is what led the FDA to release a warning in 2014. The Safety Communication officially warned against the use of power morcellators during myomectomies and hysterectomies after it was determined that 1 in 350 women undergoing these treatments had undiagnosed malignant cancer.
Aftermath of FDA Warning
“In the aftermath of the FDA warning, successive hearings and recalls, hospitals, medical facilities and surgeons are avoiding using power morcellator devices,” Rosenfeld Injury Lawyers point out. “This is because there is still no reliable way to test the patient for fibroid tumor cancer.”
While Johnson & Johnson, the leading manufacturer of power morcellation devices, has recalled its devices and asked users to return any units they own, there’s still a great division among surgeons, health care facilities, and manufacturers regarding what to do.
Patients are obviously outraged and healthcare providers are annoyed over the fact that they’ve been placed in harm’s way for using a supposedly safe device. But according to Shezad Malik, MD, JD, the origin of the problemgoes back to the pre-market testing requirements.
Power morcellators fell under the controversial 510(k) program which say manufacturers only need to show that devices are “substantially equivalent” to similar devices already on the market As a result, power morcellators were approved without any safety testing whatsoever.
Black Box Warning
In addition to releasing a written warning, the FDA has also added an official Black Box Warning – which is the strongest warning that can be placed on an approved medical device. Doctors are now required to discuss potential dangers with patients, and the FDA has formally directed surgeons not to use power morcellators with women near menopause or post-menopause.
Many women have already filed lawsuits in federal courts and many more are expected to file their own claims in the coming months. With so much negative backlash, and much more risk than reward, it’s a wonder that the FDA hasn’t come out and placed a total ban on the use of power morcellators.
The Society of Gynecologic Oncology, though, is one such body that still supports the use of morcellators. “The FDA would not approve a device using such low-quality retrospective data,” the official statement reads. “It is concerning that the FDA would now consider banning a device with a similar low level of evidence.”
The Future of Power Morcellators
As you can see, the issues surrounding power morcellators have yet to be sorted out. The FDA has taken a stance, but some believe it isn’t strong enough. Others believe it’s based on weak evidence and hasty decision-making. Everyone is entitled to their own opinions, but something needs to be done. Either the FDA should implement a full ban on the devices, or they need to invest in studies that provide stronger evidence of the risks that do or do not exist.
-
Federal Watchdog Agency Will Probe Power Morcellators
Sep 8, 2015 | Medscape
By Robert Lowes
The US Government Accountability Office (GAO) is going to launch an investigation into controversial power morcellators.
The devices shred uterine fibroids for easy removal through laparoscopic incisions. Critics say the devices accomplish that at the cost of endangering women's lives and therefore should be banned.
In April 2014, the US Food and Drug Administration (FDA) warned against using power morcellators for hysterectomies or myomectomies in most women with uterine fibroids because of the risk of spreading occult uterine cancer, found in 1 in 350 women undergoing these procedures. Six months later the FDA added a boxed warning to product labels.
Twelve members of Congress asked the GAO last month to find out why the FDA took so long to issue its warnings, given that the devices have been on the market since 1991, and studies have long established the high risk they pose for spreading occult uterine cancer. The lawmakers also want to know if an expedited FDA approval process called 510(k) missed the cancer risk of the devices before they were cleared for use. They blamed power morcellators for hundreds, if not thousands, of deaths.
Earlier this week, the GAO informed Rep. Mike Fitzpatrick (R-PA), one of the leaders of the congressional group, that it would go forward with the requested study in about 5 months.
A Device Falling Into Disfavor
The problem with power morcellators gained national attention nearly 2 years ago after anesthesiologist Amy Reed, MD, PhD, underwent a hysterectomy for fibroid removal in late 2013 and then found out that the procedure had upstaged an occult tumor. Dr Reed and her husband, cardiothoracic surgeon Hooman Noorchashm, MD, PhD, have lobbied the FDA and Congress to ban power morcellators and tighten the FDA's 510(k) approval process. Under 510(k), a manufacturer only needs to demonstrate that its product is substantially the same as a device already on the market. The physician couple says this process can put patients in harm's way because it lacks premarket safety testing and mandatory postmarket monitoring for adverse events.
Since the FDA issued its first warning about the devices in April 2014, power morcellators have fallen into disfavor. One manufacturer, Johnson & Johnson, voluntarily pulled its morcellators from the market, and major insurers have dropped or restricted coverage of morcellation procedures. As a result, fewer surgeons are using the devices.
In an interview with Medscape Medical News, Dr Noorchashm said the GAO's decision to look at the regulatory history of power morcellators was "a step in the right direction." He cautioned, however, that the GAO could be unduly influenced by morcellator manufacturers, unnamed FDA officials, and gynecologic surgeons "who are trying to sugarcoat this thing and create the illusion that there's no problem."
"We'll see if the GAO is a nonpartisan, objective third party," he said.
Dr Noorchashm's wife Dr Reed has experienced two recurrences of her cancer since her initial surgery for it. Dr Noorchashm said she is undergoing an experimental treatment that the two of them devised in lab work.
-
GAO to Investigate Morcellator Device
Sep 8, 2015 | The Perimenopause Blog
Last month I wrote a post about a controversial procedure and device used to treat fibroid tumors in women. The procedure is called “morcellation” and the device used in the procedure is called a “power morcellator.” Approved by the FDA over two decades ago to be used in surgery to remove fibroid tumors, both the device and the procedure have been linked to the spread of uterine cancer in patients who underwent the procedure.
Also in that post, was a reference to a letter written and dated August 7, 2015, by twelve members of Congress (you can download a PDF copy of that letter here ), to the Government Accountability Office (GAO), requesting that an investigation be launched into the continued use of the power morcellator, despite safety warnings issued by the FDA regarding its use. In fact, so stern were the FDA’s warnings and concerns by some in the medical community regarding the safety of the device and procedure, that even the FBI launched an investigation back in May 2015.
In response to the request by Congress to investigate the device, the GAO issued a letter dated September 1, 2015, agreeing to investigate why the device was marketed for two decades before safety warnings were issued by the FDA. You can read more about this story here.
Why is The Perimenopause Blog Interested in This Story?
Clearly, uterine fibroid tumors are a serious health issue for women. My interests lie in women’s health. Of course, I’m primarily interested in hormone health issues associated with perimenopause and menopause. But, there are many other health issues that women face in their menopause and post-menopause years, which are of interest to me as well. And believe it or not, 20 to 80% of all women will develop fibroid tumors by the time they reach their 50s.
I realize this is a huge spread statistically and as such, might actually be meaningless. There is ahuge difference in numbers between 20% and 80%. But, even if we accept the more conservative statistic of 20%, that is still a very large number of women confronted with this issue. 1 out of 5 to be exact.
But even more than this, I am always interested in the medical procedures that women are subjected to. And certainly when those procedures put women at risk for other serious health issues, such as uterine cancer for God’s sake, I’m definitely going to be interested.
I have had many readers reach out to me over the years asking if I have any knowledge or information regarding fibroid tumors. Unfortunately, I haven’t been able to help them because I have really known so little about them. However, if it is true that at least 1 in 5 women will develop fibroid tumors by the time they reach their 50s, then it is certainly a health topic that I am interested in.
I have created a new post category for fibroids and will continue to follow this story as I think it has serious implications for all women seeking health care. Subjecting ourselves to medical procedures, be what they may, which can further put our health at risk is something we should all be concerned with.
-
Sep 5, 2015 | Southern Med Law
As morcellator cancer lawsuitscontinue to be filed around the country, The U.S. Government Accountability Office (GAO) has agreed to investigate claims that laparoscopic power morcellators spread cancer during gynecological surgeries. Southern Med Law filed the first power morcellator cancer lawsuit in a U.S. federal court. Katherine Siggerud, GAO’s managing director, sent a response on September 1 to U.S. Rep. Mike Fitzpatrick (R-Pa.), who led the12-member bipartisan Congressional group in asking for the probe. The GAO conducts investigations for the U.S. Congress. According to a report by Philly.com, Ms. Siggerud wrote, “GAO accepts your request as work that is within the scope of its authority.” The legislators sent a letter to the GAO on August 7 noting that, “hundreds, if not thousands, of women in America are dead” because of power morcellators. The legislators asked the GAO to determine, among other things, whether the FDA’s expedited approval process for medical devices “sufficiently identified” the cancer risks before the power morcellators entered the marketplace.
“Southern Med Law looks forward to the outcome of the GAO’s investigation because the law firm is representing women who have been seriously or fatally injured allegedly by power morcellators,” says Dr. François Blaudeau, founder of Southern Med Law. In July, Dr. Blaudeau settled the first power morcellator cancer lawsuit filed in federal court on behalf of a Pennsylvania widower, Scott Burkhart, whose wife, Donna Burkhart, 53, died of disseminated leiomyosarcoma in February 2013. Donna Burkhart developed the cancer after undergoing a power morcellator hysterectomy in March 2012. The lawsuit was filed in the U.S. District Court, Eastern District of Pennsylvania, against morcellator manufacturers, LiNA Medical APS, Kebomed AB & LiNA Medical US. The lawsuit was settled for an undisclosed amount.(Case No. 5:14-cv-1557)
The law firm explains that laparoscopic power morcellators are used during a hysterectomy (removal of the uterus) and a myomectomy (removal of uterine fibroids). The device grinds uterine tissue into pieces so that the fragments can be removed through small (laparoscopic) incisions in the abdomen. It is during the removal of uterine tissue that undetected cancer cells are spread into the peritoneal cavity.
In November 2014, the FDA warned that power morcellators should be avoided in the majority of women who require a hysterectomy and a myomectomy due to the medical device’s potential to spread undetected cancer cells which greatly reduced a woman’s chances for long-term survival. The law firm notes that after the FDA’s announcement, national health insurance companies including Aetna Inc. and UnitedHealth, announced that they would either end or restrict coverage for uterine morcellation procedures. Additionally, in the wake of the FDA’s warning, the FBI decided to investigate power morcellators. According to CBS News, the FBI’s probe includes questioning Johnson & Johnson, the largest power morcellator manufacturer, on what it knew about the cancer risks associated with the morcellators. Johnson & Johnson suspended global sales of the devices after the FDA’s warning.
Court documents indicate that the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments on October 1 on a request from six plaintiffs who filed a request to consolidate all federally filed power morcellator cancer lawsuits. The plaintiffs are asking the panel to transfer 22 pending morcellator lawsuits, and those that are subsequently filed, to the U.S. District Court, District of Kansas. The plaintiffs, who filed claims against various morcellator manufacturers, asked for a consolidation because all the complaints allege that power morcellators used during gynecological procedures can spread and upstage cancer. (In Re: Power Morcellator Litigation, MDL Case No. 78)
-
California Couple Sue Gyrus ACMI Over Power Morcellator Cancer
Sep 8, 2015 | Top Class Actions
By Amanda Antell
A California couple has filed a power morcellator lawsuit against Gyrus ACMI, alleging that its product caused cancer to spread.
Plaintiffs Kurt and Lisa N. claim in their power morcellator lawsuit that the device caused Lisa to develop uterine cancer after a physician used the device to perform a hysterectomy.
Hysterectomies and other laparoscopic surgeries are highly delicate procedures. Power morcellators aid in the surgery by using a rotating blade to grind up tissue, which can then be removed through a tube inserted using a small incision.
While laparoscopic surgery using a power morcellator cuts down on surgery and recovery time, it can be dangerous for women with undiagnosed cancer. The devices may rupture uterine sarcoma cells, which ultimately allows for a fast and aggressive progression of uterine cancer.
There is currently no diagnostic method available to pre-determine if patients have uterine sarcoma, leaving women to find out after their power mocellator surgeries.
This was Lisa’s experience. Although her surgery was initially considered a success, a little more than a year after her surgery she was diagnosed with a severe case of uterine cancer.
Medical records revealed that she had seven cancerous tumors in her abdomen. Lisa alleges that the power morcellator device used in her surgery ruptured the uterine sarcoma, releasing deadly cancer cells into her body.
Lisa has had to undergo additional surgeries and chemotherapy to treat the tumors, and is still heavily monitored for signs of any new tumors forming. Unfortunately, there is a strong chance of recurrence.
Overview of Power Morcellator Complications
Because of their link to spreading uterine cancer, numerous medical experts advise surgeons against using power morcellators. Some hospitals already ban the use of power morcellators in their facilities.
The warnings and bans come too late for women who have already developed cancer after undergoing procedures using the devices. A number of these women have chosen to take legal action against the device’s manufacturers. The lawsuits allege that the manufacturers failed to include warnings of uterine sarcoma on the product’s warning label.
Lisa’s morcellator lawsuit claims that Gyrus knew about their device’s potential complications, but chose not to warn consumers of the possibility of uterine cancer. Lisa states that she never would have used the device if she had known about the possibility of uterine cancer.
For being allegedly responsible for manufacturing, selling, distributing, and marketing a dangerous product, Lisa and her husband are suing Gyrus Amci. The charges include negligence, false advertising, concealing information, and misrepresenting a product.
This Power Morcellator Lawsuit is Lisa N. and Kurt N. v. Gyrus ACMI, LLC, Case No. 2:14-cv-02375-GEB-DAD, in the U.S. District Court for the District of Eastern California.
-
Power Morcellator Poses Uterine Cancer Risks to Women
Sep 8, 2015 | Top Class Actions
By Karina Basso
Many women undergo gynecological surgeries for a variety of health reasons. Some common gynecological surgeries performed on women include:
myomectomy (removal of fibroids)
hysterectomy (removal of the uterus)
oophorectomy (removal of the ovaries)
salpingectomy (removal of fallopian tubes)
However, according to recent research, women who undergo these surgeries have an increased risk of developing cancer in the two years after the procedure. This is especially true if the surgeries listed above were performed using a power morcellator device, a medical tool that has become quite controversial in the medical field because of their alleged tendency to spread cancer cells at the site of surgery.
This is a starling discovery, as it is estimated that 50,000 women undergo hysterectomy morcellation procedures each year within the United States.
What is a Power Morcellator?
A power morcellator is a medical device that employs rotating blades to cut up organ tissues, which are then suctioned out of the body. Morcellation, unlike traditional myomectomies, hysterectomies, oophorectomies, and salpingectomies, requires a small incision and not a major incision through major muscle groups, allowing for a quicker recovery time for patients undergoing these types of surgeries. Because of this feature, power morcellator devices quickly rose in popularity among patients and surgeons alike.
However, because of the recent studies and morcellation lawsuits, the U.S. Food and Drug Administration (FDA) has issued a safety communication to doctors and the medical community as a whole, warning that power morcellators can spread unsuspected cancerous tissue when used during laparoscopic gynecological surgeries. The agency pointed out that one in every 350 women who undergo robotic hysterectomies or myomectomies in order to remove uterine fibroids have undiagnosed uterine sarcomas. If these uterine sarcomas are morcellated, the cancer cells can spread and potentially upstage an individual’s cancer diagnosis from stage one to stage four.
According to Cancer.net, some common signs of uterine cancer that may occur include:
Unusual vaginal or uterine bleeding
Pain and/or difficulty when urinating
Pain during sex
Pain in the pelvis or pelvic area
If you experience any of these symptoms after undergoing a gynecological surgery that used a power morcellator, you should contact your physician immediately.
Power Morcellator Litigation
Attorneys are searching for women who underwent laparoscopic hysterctomy, myomectomy, oophorectomy, or salpingectomy procedures using a morcellation device and later developed uterine cancer to bring morcellation cancer lawsuits or join morcellation cancer class action lawsuits against the manufacturers of these dangerous medical devices.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Morcellation
Full Text of Stories Below
Add recipients
Suggested